Contribution of laboratory medicine and emerging technologies to cardiovascular risk reduction via exposome analysis: An opinion of the IFCC Division on Emerging Technologies

Gruson D.; Fux E.; Kemaloǧlu Öz T.; Gouget B.; Lee W.; Shah S.; Liu Y.; Ebert S.; Greaves R.; Bernardini S.; Yang H.S.; Figueroa Montes L. · Clinical Chemistry and Laboratory Medicine (2025) · DOI: 10.1515/cclm-2024-0788

Resumen

This opinion article highlights the critical role of laboratory medicine and emerging technologies in cardiovascular risk reduction through exposome analysis. The exposome encompasses all external and internal exposures an individual faces throughout their life, influencing the onset and progression of cardiovascular diseases (CVD). Integrating exposome data with genetic information allows for a comprehensive understanding of the multifactorial causes of CVD, facilitating targeted preventive interventions. Laboratory medicine, enhanced by advanced technologies such as metabolomics and artificial intelligence (AI), plays a pivotal role in identifying and mitigating these exposures. Metabolomics provides detailed insights into metabolic changes triggered by environmental factors, while AI efficiently processes complex datasets to uncover patterns and associations. This integration fosters a proactive approach in public health and personalized medicine, enabling earlier detection and intervention. The article calls for global implementation of exposome technologies to improve population health, emphasizing the need for robust technological platforms and policy-driven initiatives to seamlessly integrate environmental data with clinical diagnostics. By harnessing these innovative technologies, laboratory medicine can significantly contribute to reducing the global burden of cardiovascular diseases through precise and personalized risk mitigation strategies.